The growth of Viagra and its impact on the medicinal landscape presents a intricate question for investors. While the early sales data were impressive, the exclusivity has expired, leading to a wave of copycat alternatives that are reducing profit. Furthermore, the market is facing difficulties related to demographic trends and evolving healthcare